Linda Liu, Ph.D. | Vice President, Translational Sciences
|Dr. Liu has more than 20 years of research and industry experience with broad knowledge and proven success in the discovery and development of biological drug candidates in oncology and autoimmune diseases. She was one of the founding members of Amplimmune (now MedImmune/AstraZeneca) where she held various key positions with increasing responsibilities, including Executive Director of Translational Science/Scientific Affairs and VP of New Products. Prior to that, she served as Senior Director of Biological Product Development at MaxCyte, where she was responsible for development, in vitro and in vivo characterization and manufacture of various gene & cell based therapeutics including CAR-T, CAR-NK & DC therapies. Dr. Liu is an author or co-author of many research and review articles in peer-reviewed journals and book chapters in the areas of cancer immunotherapy, gene/cell therapy and cell biology. She is an inventor of numerous US and European patents and patent applications. Dr. Liu received her Ph.D. degree in Virology and Cell Biology from the University of Texas, Austin and her B.S. degree in Virology and Molecular Biology from Wuhan University in China. She conducted her postdoctoral training in Tumor Cell Biology at the St. Jude Children’s Research Hospital.||• Michael Richman
President & CEO
• James B. Bingham, Ph.D.
Senior Vice President, Development &
• Sol Langermann, Ph.D.
Senior Vice President, Research
• Linda Liu, Ph.D.
Vice President, Translational Sciences
• Timothy Mayer, Ph.D.
Vice President, Business Development
• Sebastien Maloveste, Ph.D.
Senior Director, Business Development
• Dallas Flies, Ph.D.
Director, Immunology and Discovery Research